Nancy Tich

Statistics

Publications

Citations

257

H-Index

Active since

1994

Affiliations

Zynerba Pharmaceuticals (United States)(Current)

The University of Queensland

Nancy Tich is an author at Zynerba Pharmaceuticals (United States) specializing in medicine, x-linked neurodevelopmental disorders, and genetic disorders.

Publications per year

1994–2022

Publications

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Helen Heussler, Jonathan Cohen, Natalie Silove et al. · Journal of Neurodevelopmental Disorders · 2019 · 105 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +15

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Elizabeth Berry‐Kravis, Randi J. Hagerman, Dejan B. Budimirovic et al. · Journal of Neurodevelopmental Disorders · 2022 · 66 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +14

Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis

David J. Hunter, G. Oldfield, Nancy Tich et al. · Osteoarthritis and Cartilage · 2018 · 49 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.

A. David Rodrigues, J L Ferrero, Maria Amann et al. · Drug Metabolism and Disposition · 1994 · 37 citations

Medicine, Biochemistry, Pharmacology +9

1–4 of 4